

Please try another search
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Name | Age | Since | Title |
---|---|---|---|
Lee Sweeney | - | - | Member of Scientific Advisory Board |
Jonathan C. Fox | 67 | 2023 | Independent Director |
Peter A. Thompson | 64 | 2017 | Co-Founder & Independent Chairman |
Kevin Koch | 64 | 2017 | President, CEO & Director |
Jonathan D. Root | 64 | 2019 | Independent Director |
Badreddin Edris | 37 | 2017 | Co-Founder & Independent Director |
Barry J. Byrne | - | - | Member of Scientific Advisory Board |
Leslie A. Leinwand | - | - | Member of Scientific Advisory Board |
Laura A. Brege | 66 | 2020 | Independent Director |
Craig McDonald | - | 2020 | Member of the Scientific Advisory Board |
Alan J. Russell | 54 | 2017 | Co-Founder, Chief Scientific Officer & Director |
Arlene M. Morris | 73 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review